Leeward Financial Partners LLC Invests $5.31 Million in Natera, Inc. $NTRA

Key Points

• Leeward Financial Partners initiated a $5.31 million position in Natera during the second quarter, while institutional investors collectively own 99.90% of the company’s stock.
• Natera reported quarterly revenue of $752.75 million, up 37.7% year over year and above analyst expectations, while its adjusted loss of $0.47 per share narrowly beat estimates.
• Analyst sentiment remains positive, with a “Moderate Buy” consensus and an average price target of $319.38, although insiders have sold approximately $41.3 million of shares over the past 90 days.

Leeward Financial Partners LLC bought a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 19,553 shares of the medical research company's stock, valued at approximately $5,308,000. Natera accounts for approximately 1.4% of Leeward Financial Partners LLC's investment portfolio, making the stock its 19th biggest holding.

A number of other large investors have also recently bought and sold shares of NTRA. Integrated Wealth Concepts LLC raised its position in Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company's stock worth $221,000 after buying an additional 96 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in shares of Natera by 68.3% in the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company's stock valued at $644,000 after acquiring an additional 1,847 shares during the last quarter. Focus Partners Wealth boosted its holdings in shares of Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company's stock valued at $847,000 after acquiring an additional 474 shares during the last quarter. Sivia Capital Partners LLC purchased a new stake in shares of Natera in the 2nd quarter valued at $298,000. Finally, WINTON GROUP Ltd acquired a new stake in shares of Natera in the second quarter worth $558,000. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Price Performance

NASDAQ:NTRA opened at $309.93 on Friday. The company has a 50 day moving average price of $263.76 and a 200-day moving average price of $226.40. Natera, Inc. has a 1-year low of $156.71 and a 1-year high of $326.03. The firm has a market cap of $44.67 billion, a price-to-earnings ratio of -227.89 and a beta of 1.51.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. The firm had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm's quarterly revenue was up 37.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.74) earnings per share. On average, sell-side analysts anticipate that Natera, Inc. will post -1.11 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Solomon Moshkevich sold 3,410 shares of the firm's stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80. Following the sale, the insider directly owned 129,019 shares in the company, valued at $34,264,866.02. This trade represents a 2.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Herm Rosenman sold 16,530 shares of Natera stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total value of $4,132,500.00. Following the completion of the transaction, the director owned 4,250 shares of the company's stock, valued at approximately $1,062,500. This represents a 79.55% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 181,045 shares of company stock valued at $41,330,968. Insiders own 5.05% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on NTRA shares. Royal Bank Of Canada raised their target price on shares of Natera from $275.00 to $350.00 and gave the stock an "outperform" rating in a report on Friday, August 7th. UBS Group set a $260.00 price target on shares of Natera in a report on Wednesday, June 24th. The Goldman Sachs Group assumed coverage on Natera in a research report on Friday, June 5th. They set a "neutral" rating and a $245.00 price target on the stock. JPMorgan Chase & Co. lifted their price objective on Natera from $315.00 to $360.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. Finally, Citigroup boosted their price objective on Natera from $315.00 to $365.00 and gave the company a "buy" rating in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $319.38.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source